Dexcom (DC4) AI Stock Analysis

Dexcom

(XETRA:DC4)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Recurring CGM RevenueDexcom’s sensor replacement cycle creates recurring revenue and supports customer retention after initial adoption. This model provides a durable base for forecasting, while ongoing reimbursement, channel access, and connected-care partnerships can expand utilization and deepen the value of each customer relationship.

Negative Factors

Weaker Cash ConversionRecent deterioration in cash conversion means reported earnings are translating into less incremental cash than before. Although absolute cash generation remains substantial, higher investment or working-capital needs could reduce funding available for expansion, buybacks, and other capital-allocation priorities.

Dexcom (DC4) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 31.05B
Dividend Yield: ―
Average Volume (3M): 188
Price to Earnings (P/E): 31.8
Beta (1Y): 1.03
Revenue Growth: 7.61%
EPS Growth: 35.83%
Country: Germany
Employees: 11,050
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Dexcom Business Overview & Revenue Model

Company Description

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individua...

Dexcom Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q3-2026)|% Change Since:6.50%|Next Earnings Date:Feb 10, 2027

Earnings Call SentimentPositive

The call was strongly positive. Dexcom reported 11% worldwide revenue growth, 14% U.S. growth, continued market-share gains, near-record new patient starts, significant gross-margin and EBITDA-margin expansion, strong cash generation, raised operating and EBITDA margin guidance, and substantial progress in clinical evidence, product launches, manufacturing, and future access expansion. The main challenges were slower international growth, near-term Ireland ramp effects, incremental foreign-exchange headwinds, higher operating expenses, and the loss of preferred access under a PBM representing less than 4% of U.S. revenue. Highlights significantly outweighed the lowlights.

Positive Updates

Third-Quarter Revenue Growth

Worldwide third-quarter revenue was $1.34 billion versus $1.21 billion in the third quarter of 2025, representing 11% growth on both a reported and organic basis.

Negative Updates

Slower International Revenue Growth

International revenue increased 5% on both a reported and organic basis to $375 million. Management said growth was affected by lapping multiple reimbursement wins from the second half of 2025 and expects international revenue to normalize back to higher organic growth levels at the start of next year.

Company Guidance

Dexcom updated full year revenue guidance to be in the range of $5.20 billion to $5.25 billion, representing growth of 12% to 13% for the year, with midpoint fourth quarter growth of 10%; it maintained full year non-GAAP gross profit margin guidance at approximately 64% and increased non-GAAP operating profit margin guidance to approximately 24% and adjusted EBITDA margin guidance to approximately 32%. Dexcom expects to convert nearly 50% of its U.S. customer base to G7 15 Day by year-end, expects CMS to announce a type 2 non-insulin coverage decision this year with coverage taking effect middle of next year, and is still targeting GA for either launching at the end of next year or early '28, depending on regulatory review time lines.

Dexcom Risk Analysis

Dexcom disclosed 75 risk factors in its most recent earnings report. Dexcom reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Dexcom Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:DC4 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDT	74Outperform	$123.49B	23.60	10.60%	2.96%	9.77%	12.28%
ABT	69Neutral	$183.77B	39.33	9.12%	2.37%	10.00%	―
PODD	68Neutral	$10.38B	27.93	26.69%	―	29.41%	59.39%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TNDM	47Neutral	$1.33B	-20.58	-45.97%	―	3.92%	70.03%
SENS	43Neutral	$502.83M	-4.19	-165.83%	―	90.63%	-11.42%

* Healthcare Sector Average

Performance Comparison

DE:DC4 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:DC4	Dexcom	75.40	23.21	44.47%
ABT	Abbott Laboratories	106.20	-14.64	-12.11%
PODD	Insulet	149.68	-169.09	-53.04%
MDT	Medtronic	96.54	9.23	10.58%
TNDM	Tandem Diabetes Care	19.11	4.75	33.08%
SENS	Senseonics Holdings Inc.	9.51	2.63	38.23%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Dexcom AI Stock Analysis